ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Bruce Montgomery,¹ on behalf of Thian Kheoh,² Arturo Molina,² Jinhui Li,³ Joaquim Bellmunt,⁴ Charles J. Ryan,⁵ NamPhuong Tran,² Yohann Loriot,⁶ Eleni Efstathiou,⁷ Howard I. Scher,⁸ Johann S. de Bono⁹ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

¹University of Washington, Seattle, WA; ²Janssen Research & Development, Los Angeles, CA; ³Janssen Research & Development, Raritan, NJ; ⁴Dana-Farber Cancer Institute, Boston, MA; ⁵Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; ⁶Institut Gustave Roussy, Villejuif, France; ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, University of Athens, Greece; ⁸Memorial Sloan-Kettering Cancer Center, New York, NY; ⁹The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK

__________________________________________________

R. Bruce Montgomery, MD is associate professor, Medical Oncology Division, University of Washington School of Medicine; affiliate member, Clinical Research Division, Fred Hutchinson Cancer Research Center; and medical oncologist, Seattle Cancer Care Alliance

He received his medical degree from Duke University School of Medicine, did residency at Brigham and Women's Hospital's internal medicine division and his fellowship at the University of Washington in the division of medical oncology.

His areas of clinical expertise include treatment of high risk and advanced prostate cancer, treatment of bladder and testicular cancers, and drug resistance to hormonal therapy and taxane chemotherapy. 

View Full ASCO 2013 Coverage